Zobrazeno 1 - 10
of 10
pro vyhledávání: '"van Dongen MGJ"'
Publikováno v:
Compendium behandeling van het mammacarcinoom, 43-53
ISSUE=3e;STARTPAGE=43;ENDPAGE=53;TITLE=Compendium behandeling van het mammacarcinoom
ISSUE=3e;STARTPAGE=43;ENDPAGE=53;TITLE=Compendium behandeling van het mammacarcinoom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::586c2c44516ab467bb44020374f9b46c
https://pure.eur.nl/en/publications/725b07bb-f857-4c66-99ca-e3c33be37aaa
https://pure.eur.nl/en/publications/725b07bb-f857-4c66-99ca-e3c33be37aaa
Autor:
Nederlof I; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Isaeva OI; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Graaf M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Gielen RCAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bakker NAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Rolfes AL; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Garner H; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Boeckx B; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Traets JJH; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Maaker M; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Brussel T; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Chelushkin M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Champanhet E; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lopez-Yurda M; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van de Vijver K; Department of Pathology, UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium.; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Berg JG; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Klioueva N; Department of Pathology, OLVG Hospital, Amsterdam, the Netherlands., Mann RM; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Duijnhoven FH; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Skinner V; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Luykx S; Medical Oncology Department, Tergooi Hospital - locatie Hilversum, Hilversum, the Netherlands., Kerver E; Department of Oncology, OLVG Hospital, Amsterdam, the Netherlands., Kalashnikova E; Natera, San Carlos, CA, USA., van Dongen MGJ; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Linn SC; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Visser KE; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands., Salgado R; Department of Pathology, ZAS hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Wessels LFA; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Drukker CA; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Schumacher TN; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lambrechts D; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.; VIB Center for Cancer Biology, Leuven, Belgium., Kok M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.
Publikováno v:
Nature medicine [Nat Med] 2024 Sep 16. Date of Electronic Publication: 2024 Sep 16.
Autor:
Geurts VCM; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Voorwerk L; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Balduzzi S; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Salgado R; Department of Pathology, ZAS, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Victoria, Australia., Van de Vijver K; Department of Pathology, University Hospital Ghent, Cancer Research Institute Ghent (CRIG), Ghent, Belgium., van Dongen MGJ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kemper I; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Heuver M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sparreboom W; Astra Zeneca, The Hague, the Netherlands., Haanen JBAG; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Horlings HM; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kok M; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: M.Kok@nki.nl.
Publikováno v:
Breast (Edinburgh, Scotland) [Breast] 2023 Aug; Vol. 70, pp. 76-81. Date of Electronic Publication: 2023 Jun 27.
Autor:
Voorwerk L; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Isaeva OI; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Balduzzi S; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Chelushkin M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bakker NAM; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Champanhet E; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Garner H; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Sikorska K; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kemper I; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Maaker M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Geel JJL; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Boers J; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., de Boer M; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, the Netherlands., Salgado R; Department of Pathology, GZA-ZNA hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., van Dongen MGJ; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Visser KE; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands., Schumacher TN; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wessels LFA; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Jager A; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, the Netherlands., Schröder CP; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Linn SC; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Kok M; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.
Publikováno v:
Nature cancer [Nat Cancer] 2023 Apr; Vol. 4 (4), pp. 535-549. Date of Electronic Publication: 2023 Apr 10.
Autor:
Shapira-Frommer R; Sheba Medical Center, Ramat Gan, Israel. Electronic address: ronnie.shapira@sheba.health.gov.il., Mileshkin L; Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: linda.mileshkin@petermac.org., Manzyuk L; N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia., Penel N; Centre Oscar Lambret and Lille University, Lille, France. Electronic address: n-penel@o-lambret.fr., Burge M; Royal Brisbane and Women's Hospital, Herston, QLD, Australia. Electronic address: matthew.burge@health.qld.gov.au., Piha-Paul SA; University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: spihapau@mdanderson.org., Girda E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Electronic address: eg535@cinj.rutgers.edu., Lopez Martin JA; 12 de Octubre University Hospital & Research Institute (i+12), Madrid, Spain., van Dongen MGJ; Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: mg.v.dongen@nki.nl., Italiano A; Institut Bergonié and University of Bordeaux, Bordeaux, France. Electronic address: a.italiano@bordeaux.unicancer.fr., Xu L; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: lei_xu2@merck.com., Jin F; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: fan.jin@merck.com., Norwood K; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: kevin.norwood@merck.com., Ott PA; Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: patrick_ott@dfci.harvard.edu.
Publikováno v:
Gynecologic oncology [Gynecol Oncol] 2022 Aug; Vol. 166 (2), pp. 211-218. Date of Electronic Publication: 2022 Mar 28.
Autor:
Marabelle A; Gustave Roussy, INSERM U1015, Université Paris Saclay, Villejuif, France. Electronic address: aurelien.marabelle@gustaveroussy.fr., Cassier PA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Fakih M; City of Hope National Medical Center, Duarte, CA, USA., Kao S; Chris O'Brien Lifehouse, Camperdown, NSW, Australia., Nielsen D; Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark., Italiano A; Early Phase Trials Unit, Institut Bergonié and University of Bordeaux, Bordeaux, France., Guren TK; Oslo University Hospital, Oslo, Norway., van Dongen MGJ; Antoni van Leeuwenhoek, Netherlands Cancer Institute Amsterdam, Amsterdam, Netherlands., Spencer K; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Bariani GM; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Santoro A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy; IRCCS Humanitas Research Hospital-Humanitas Cancer Center, Rozzano, Italy., Shah M; Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Asselah J; McGill University, Montreal, QC, Canada., Iqbal S; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Takahashi S; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Piha-Paul SA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ott PA; Dana-Farber Cancer Institute, Boston, MA, USA., Chatterjee A; Merck & Co, Kenilworth, NJ, USA., Jin F; Merck & Co, Kenilworth, NJ, USA., Norwood K; Merck & Co, Kenilworth, NJ, USA., Delord JP; Institut Claudius Regaud IUCT-Oncopole, Toulouse, France.
Publikováno v:
The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2022 May; Vol. 7 (5), pp. 446-454. Date of Electronic Publication: 2022 Feb 01.
Autor:
Molenaar-Kuijsten L; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Braal CL; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Groenland SL; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., de Vries N; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., Vulink AJE; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, The Netherlands., van Dongen MGJ; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center, Utrecht University, Utrecht, The Netherlands.; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Steeghs N; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Feb; Vol. 111 (2), pp. 477-484. Date of Electronic Publication: 2021 Nov 06.
Autor:
Groenland SL; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. s.groenland@nki.nl., Martínez-Chávez A; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., van Dongen MGJ; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Schinkel AH; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Steeghs N; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2020 Dec; Vol. 59 (12), pp. 1501-1520.
Autor:
van Dongen MGJ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kok M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: m.kok@nki.nl.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2020 May; Vol. 31 (5), pp. 556-557. Date of Electronic Publication: 2020 Mar 11.
Autor:
Masroor S; Maastricht University, Maastricht, The Netherlands., van Dongen MGJ; Netherlands Cancer Institute, Amsterdam, The Netherlands., Alvarez-Jimenez R; Amsterdam University Medical Center, Amsterdam, The Netherlands., Burggraaf K; Centre for Human Drug Research, Leiden, The Netherlands., Peletier LA; Leiden University, Leiden, The Netherlands., Peletier MA; Eindhoven University of Technology, Eindhoven, The Netherlands. m.a.peletier@tue.nl.
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2019 Dec; Vol. 46 (6), pp. 553-564. Date of Electronic Publication: 2019 Sep 30.